Anti-HCV and HBsAg Test in Delhi

Anti HCV + HBsAg Test at Home 

The Anti HCV + HBsAg combination blood test screens simultaneously for two of the most clinically significant viral hepatitis infections: Hepatitis B, through the Hepatitis B Surface Antigen (HBsAg) test, and Hepatitis C, through the Anti-HCV antibody test. Both infections target the liver and can progress silently over decades to cirrhosis, liver failure, and hepatocellular carcinoma, one of the most serious and difficult-to-treat cancers.

Despite this severity, both Hepatitis B and Hepatitis C are frequently asymptomatic in the early and even the chronic phase. Routine screening is therefore the most effective strategy for detection, and testing for both infections in a single blood draw is clinically efficient because the routes of transmission overlap considerably.

MAX@Home makes this important screening accessible at home. A certified phlebotomist collects your sample at a time you choose, and your digitally authenticated report is delivered within 12 to 24 hours, ready for clinical follow-up.

What the HBsAg Test Detects

HBsAg, or Hepatitis B Surface Antigen, is a protein found on the outer surface of the Hepatitis B virus particle. It is the first serological marker to appear following HBV infection, typically becoming detectable in the blood within 1 to 9 weeks of exposure, well before any symptoms develop.

Key facts about HBsAg

• A positive HBsAg indicates that the Hepatitis B virus is actively present in the blood and that the person is currently infectious.
• If HBsAg remains positive for more than six months, the infection is classified as chronic Hepatitis B.
• In adults, approximately 90 to 95% of Hepatitis B infections resolve naturally. The remaining 5 to 10% progress to chronic infection.
• Infants and young children infected with HBV have a much higher rate of developing chronic infection, up to 90% for those infected at birth.
• Chronic HBsAg-positive individuals face elevated long-term risks of cirrhosis and hepatocellular carcinoma.
• Following successful Hepatitis B vaccination, HBsAg is negative and Anti-HBs (surface antibody) is positive - a protective immune response.

HBsAg in pregnancy

Screening for HBsAg in pregnancy is a standard component of antenatal care because vertical transmission from mother to infant at or around the time of birth is highly efficient and carries a 90% risk of chronic infection in the newborn. When an expectant mother is found to be HBsAg-positive, the infant receives Hepatitis B immunoglobulin (HBIG) along with the first dose of the Hepatitis B vaccine within 12 hours of birth. This combined passive-active immunoprophylaxis is highly effective at preventing neonatal infection. Pregnant women who have not been previously screened benefit greatly from home-based testing for its convenience during what is often a period of frequent healthcare appointments.

What the Anti-HCV Test Detects

Anti-HCV detects IgG antibodies produced by the immune system in response to exposure to the Hepatitis C virus. Unlike HBsAg, which directly detects the virus, Anti-HCV detects the immune response to the virus. This distinction is clinically important.

Key facts about Anti-HCV

• A reactive Anti-HCV result indicates past or present exposure to the Hepatitis C virus.
• It does not distinguish between an active infection and a past infection that has been cleared.
• Approximately 20 to 30% of people infected with HCV clear the virus naturally through their immune response; residual antibodies remain for life.
• A reactive Anti-HCV must always be followed by an HCV RNA PCR test to determine whether the virus is currently active.
• Anti-HCV antibodies typically become detectable 8 to 11 weeks after HCV exposure. In rare cases the window can extend to 6 months.

The HCV RNA PCR as the essential next step

The Anti-HCV test is a screening tool, not a diagnostic endpoint. When Anti-HCV is reactive, the HCV RNA PCR test determines whether the virus is currently present in the blood and replicating. A positive HCV RNA confirms active Hepatitis C requiring treatment. A negative HCV RNA in the setting of a reactive antibody indicates past infection that has been cleared, either spontaneously or after prior treatment. This distinction is critical because the management of active infection, which involves curative antiviral treatment, is entirely different from the management of past cleared infection, which requires reassurance and ongoing surveillance for reinfection risk.

Why Test Hepatitis B and Hepatitis C Together

Both infections share overlapping routes of transmission, making dual screening practical and efficient for anyone at elevated risk.

• Blood-to-blood transmission is a common route for both HBV and HCV, including through needle-sharing, unscreened blood products, and non-sterile medical or cosmetic procedures.
• Healthcare workers exposed to blood are at risk of both infections and benefit from dual screening as part of occupational health monitoring.
• A single blood draw captures the status of both infections simultaneously, reducing the cost and inconvenience of two separate test orders.
• Concurrent HBV and HCV infection carries a significantly higher risk of advanced liver disease than either infection alone.
• For pre-marital, pre-operative, and antenatal screening panels, the combined test is the standard of care.

Clinical Significance and Public Health Context

The burden of Hepatitis B

Chronic Hepatitis B affects an estimated 296 million people globally. Most are unaware of their infection. Individuals infected as infants or young children carry the highest lifetime risk of liver cancer after decades of clinically silent infection. Early detection through HBsAg screening allows antiviral treatment with nucleoside analogues to suppress viral replication, slow liver fibrosis, and significantly reduce the risk of cirrhosis and cancer. Household contacts and sexual partners can be vaccinated to prevent further transmission.

The burden of Hepatitis C

Chronic Hepatitis C affects approximately 58 million people worldwide. The HCV landscape has been transformed by direct-acting antiviral (DAA) medications. Current DAA regimens achieve cure rates exceeding 95% across all HCV genotypes with 8 to 12 weeks of once-daily oral treatment and minimal side effects. Curing HCV dramatically slows further liver damage and substantially reduces long-term cancer risk, even in patients with existing fibrosis. Because HCV has no vaccine, screening is the only strategy for identifying people who need treatment.

Concurrent Hepatitis B and C infection

When both HBsAg and Anti-HCV are positive, the patient has evidence of concurrent infection with both viruses. This combination demands urgent specialist hepatology review. Managing co-infection requires careful sequencing and co-ordination of treatment for both viruses, as standard therapies for each may interact, and the combined viral load accelerates liver damage more than either virus alone.

Hepatitis B and the goal of functional cure

Unlike Hepatitis C, Hepatitis B cannot currently be eradicated from the body in most cases. Existing antiviral treatment for chronic Hepatitis B suppresses viral replication and keeps the infection under control, significantly reducing the risk of cirrhosis and hepatocellular carcinoma. The goal in Hepatitis B management is therefore viral suppression and long-term monitoring rather than short-course eradication. Research into a functional cure for Hepatitis B, meaning sustained suppression of the virus after stopping treatment, is ongoing and represents one of the most active areas of hepatology research. Early identification through HBsAg testing is the prerequisite for getting individuals into a management programme that reduces their cancer risk over a lifetime.

Who Should Get the Anti HCV + HBsAg Test

• Healthcare workers with potential occupational exposure to blood or body fluids.
• Individuals who received blood transfusions or organ transplants, particularly before universal blood donor screening was introduced in the 1990s.
• Those who have ever used injected drugs, even on a single occasion in the past.
• People with multiple sexual partners or a history of sexually transmitted infections.
• Those born to mothers who are HBsAg-positive or HCV-positive.
• Individuals born in or who have lived in regions with high Hepatitis B or C prevalence.
• Pregnant women - routine HBsAg screening is standard care to enable newborn vaccination and immunoglobulin prophylaxis.
• Patients with unexplained elevation in liver enzymes (ALT and AST) without an identified cause.
• Those undergoing dialysis, where infection-control risks are higher.
• Anyone who has undergone tattooing, body piercing, or acupuncture in non-sterile conditions.
• Individuals seeking a comprehensive health check or pre-marital screen.

How to Prepare for Sample Collection

Before the test

• Fasting is not required for this test.
• No specific dietary or lifestyle restrictions apply before collection.
• The test can be scheduled at any convenient time of day.
• Inform your doctor of any recent illnesses or immunosuppressive medications, as these can occasionally affect antibody titres.

Collection details

• Sample type: blood (serum).
• A certified MAX@Home phlebotomist visits your home at your scheduled time with sterile, single-use equipment.
• Report turnaround: typically 12 to 24 hours from sample receipt at the accredited partner lab.

After your sample is collected

• Keep the venepuncture site clean and apply gentle pressure if minor bleeding occurs.
• You will receive a notification once your report is available, usually within 12 to 24 hours.
• If the Anti-HCV result is reactive, prompt follow-up with an HCV RNA PCR test should be arranged before drawing any clinical conclusions.
• If HBsAg is positive, share the report with a gastroenterologist or hepatologist promptly for further characterisation of the infection and initiation of appropriate management.

Understanding Your Anti HCV + HBsAg Results

HBsAg result interpretation

• Negative: No active Hepatitis B infection detected. If unvaccinated, vaccination is strongly recommended.
• Positive: Active HBV infection confirmed. Further testing required: HBeAg, Anti-HBe, Anti-HBc (total and IgM), HBV DNA viral load, liver function tests, and abdominal ultrasound.

Anti-HCV result interpretation

• Non-reactive: No HCV antibodies detected. HCV exposure is unlikely. If recent exposure is suspected within the antibody window period, a repeat test or direct HCV RNA PCR test may be advised.
• Reactive: HCV antibodies present. Confirms past or present exposure. An HCV RNA PCR test must follow to determine whether the virus is still active.
• Reactive Anti-HCV with positive HCV RNA: Active Hepatitis C confirmed. Treatment planning with a hepatologist should begin promptly.
• Reactive Anti-HCV with negative HCV RNA: Past infection that has been cleared, either spontaneously or following successful prior treatment.

When both markers are positive

Both a positive HBsAg and a reactive Anti-HCV in the same patient indicates co-infection with Hepatitis B and Hepatitis C. This requires urgent specialist hepatology review. The two infections together accelerate liver disease progression and require co-ordinated management to sequence treatment safely and effectively.

How to Book Your Anti HCV + HBsAg Test with MAX@Home

1.  Open the MAX@Home website or app and search for the Anti HCV + HBsAg combination test.

2.  Select your preferred date and time. No fasting needed, so any time of day works.

3.  A certified phlebotomist arrives at your home with sterile, single-use equipment.

4.  The blood sample is collected and transported to the accredited partner laboratory.

5.  Your digitally authenticated report is delivered within 12 to 24 hours to your registered contact.

Why Choose MAX@Home for This Test

• Many people delay hepatitis screening due to inconvenience, stigma concerns, or difficulty taking time off work. Home collection removes all of these barriers.
• The privacy of home-based testing is especially relevant for a screening test that carries social sensitivity for some individuals.
• The fast 12 to 24 hour turnaround means critical results reach your physician quickly, enabling timely follow-up or specialist referral.
• For pregnant women, home collection at a convenient time in the first trimester makes antenatal HBsAg screening easy to fit around appointments.
• Accredited partner laboratories maintain the sensitivity and specificity standards required for population-level viral hepatitis screening.
• Early diagnosis of Hepatitis B or C directly translates to better treatment outcomes, slower disease progression, and prevention of transmission to others.